Clinical Trial

MHB018A Treatment in Patients With Chronic Thyroid Eye Disease

Study acronym: Interventional
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered Q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from chronic TED.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2026-03-27
Trial Details
NCT Number NCT07257185
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Thyroid Eye Disease (TED)
Enrollment 150 participants
Start Date 2026-03-17
Primary Completion 2027-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-30